

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**


**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : <b>C07D 471/08, A61K 31/55</b> <b>// (C07D 471/08, 223:00, 221:00)</b>		A1	(11) International Publication Number: <b>WO 92/15585</b> (43) International Publication Date: 17 September 1992 (17.09.92)
(21) International Application Number: <b>PCT/US92/00113</b>			(72) Inventor; and
(22) International Filing Date: 17 January 1992 (17.01.92)			(75) Inventor/Applicant ( <i>for US only</i> ) : LOWE, John, A., III [US/US]; 28 Coveside Lane, Stonington, CT 06378 (US).
(30) Priority data: 663,238 1 March 1991 (01.03.91)	US		(74) Agents: RICHARDSON, Peter, C. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).
(60) Parent Application or Grant (63) Related by Continuation US Filed on 663,238 (CON) 1 March 1991 (01.03.91)			(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US.
(71) Applicant ( <i>for all designated States except US</i> ): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).			Published <i>With international search report.</i>

(54) Title: 1-AZABICYCLO[3.2.2]NONAN-3-AMINE DERIVATIVES



## (57) Abstract

The present invention relates to novel 1-azabicyclo[3.2.2]nonan-3-amine derivatives of formula (I) wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each independently selected from hydrogen, fluorine, chlorine, bromine, trifluoromethyl, alkyl having from one to three carbon atoms, alkoxy having from one to three carbon atoms, carboxy, alkoxy carbonyl having from one to three carbon atoms in the alkoxy moiety, and benzyloxycarbonyl. These compounds are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	CN	Guinea	NL	Netherlands
BG	Bulgaria	CR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

5

1-AZABICYCLO[3.2.2]NONAN-3-AMINE DERIVATIVESBackground of the Invention

This invention relates to novel 1-azabicyclo[3.2.2]-nonan-3-amine derivatives.

The compounds of the invention have the ability to antagonize substance P. They are, therefore, useful in treating conditions such as intestinal disorders, central nervous system disorders, inflammatory diseases, pain and migraine. The present invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treating the foregoing conditions.

E.J. Warawa in U.S. Patent No. 3,560,510 refers to certain 3-amino-2-benzhydrylquinuclidines as being useful as diuretic agents, with the corresponding unsubstituted 3-benzylamino compounds acting as intermediates for same. Additionally, E.J. Warawa et al. in the Journal of Medicinal Chemistry, Vol. 18, p. 587 (1975) extends this work to other members of the series wherein the 3-amino moiety is either ethylamino, beta-phenylethylamino, beta-isopropyl-amino or 2-furylamino, but in no instance is there any substitution on the phenyl group itself and the 2-benzhydryl moiety is always symmetrically substituted (or unsubstituted). Neither of the aforementioned documents teaches or suggests any of these compounds to be useful as substance P antagonists.

PCT Patent Application PCT/US 89/05338, filed November 20, 1989 refers to cis-3-[(cyclic)methylamino]-2-[(alpha-substituted)aryl|methyl]quinuclidines, 3-[(cyclic)-methylamino]-2-[(alpha-substituted)aryl|methyl]quinuclidines and cis-3-[(cyclic)methyleneamino]-2-[alpha-substituted]-aryl|methyl]quinuclidines and states that they are useful as substance P antagonists. PCT Patent Application PCT/US 90/00116 refers to carbocyclic ring systems wherein one of the rings is substituted with an amino group and wherein one carbon atom in each of two of the rings may be replaced by a hetero atom, and states that they are useful as substance P antagonists.

U. S. Patent Application Serial No. 07/557,442 refers to azatricyclic quinuclidine derivatives and states that such compounds are useful as substance P antagonists.


Substance P is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being so-named because of their prompt stimulatory action on smooth muscle tissue. More specifically, substance P is a pharmacologically-active neuropeptide that is produced in mammals (having originally been isolated from gut) and possesses a characteristic amino acid sequence that is illustrated by D. F. Veber

-2-

et al. in U.S. Patent No. 4,630,283. The wide involvement of substance P and other tachykinins in the pathophysiology of numerous diseases has been amply demonstrated in the art. For instance, substance P has recently been shown to be involved in the transmission of pain or migraine [see B.E.B. Sandberg et al., Journal of Medicinal Chemistry, Vol. 25, p. 1009 (1982)], as well as in central nervous system disorders such as anxiety and schizophrenia, in respiratory and inflammatory diseases such as asthma and rheumatoid arthritis, respectively, and in gastrointestinal disorders and diseases of the GI tract, like ulcerative colitis and Crohn's disease, etc. (see D. Regoli in "Trends in Cluster Headache," Edited by F. Sicuteli et al., Elsevier Scientific Publishers, Amsterdam, 1987, pp. 85-95).

## Summary of the Invention

The present invention relates to compounds of the formula



wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> are each independently selected from hydrogen, fluorine, chlorine, bromine, trifluoromethyl, alkyl having from one to three carbon atoms, alkoxy having from one to three carbon atoms, carboxy, alkoxycarbonyl having from one to three carbon atoms in the alkoxy moiety, and benzyloxycarbonyl; and the pharmaceutically acceptable salts of such compounds.

Examples of compounds of the formula I include:

2-(Diphenylmethyl)-N-((2,4-dimethoxyphenyl)methyl)-1-azabicyclo[3.2.2]nonan-3-amine;  
2-(Diphenylmethyl)-N-((2,5-dimethoxyphenyl)methyl)-1-azabicyclo[3.2.2]nonan-3-amine;

-3-

2-(Diphenylmethyl)-N-((2-methoxy, 5-chlorophenyl)methyl)-1-azabicyclo[3.2.2]nonan-3-amine;

2-(Diphenylmethyl)-N-((2-methoxy, 5-fluorophenyl)methyl)-1-azabicyclo[3.2.2]nonan-3-amine;

5       2-(Di(4-fluorophenyl)methyl)-N-((2-methoxyphenyl)methyl)-1-azabicyclo[3.2.2]nonan-3-amine;

          2-(Di(4-fluorophenyl)methyl)-N-((2,4-dimethoxyphenyl)methyl)-1-azabicyclo[3.2.2]nonan-3-amine;

10      2-((2-Fluorophenyl), (3-fluorophenyl)methyl)-N-((2-methoxyphenyl)methyl)-1-azabicyclo[3.2.2]nonan-3-amine;

          2-(Di(3-fluorophenyl)methyl)-N-((2,4-dimethoxyphenyl)methyl)-1-azabicyclo[3.2.2]nonan-3-amine;

          2-((Phenyl), (thienyl)methyl)-N-((2-methoxyphenyl)methyl)-1-azabicyclo[3.2.2]nonan-3-amine; and

15      2-(Di(2-thienyl)methyl)-N-((2-methoxyphenyl)methyl)-1-azabicyclo[3.2.2]nonan-3-amine.

A preferred compound of the formula I is 2-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-1-azabicyclo[3.2.2]nonan-3-amine.

The present invention also relates to a pharmaceutical composition for treating or preventing a condition selected from the group consisting of inflammatory diseases (e.g., arthritis, psoriasis, asthma and inflammatory bowel disease), anxiety, depression or dysthymic disorders, colitis, psychosis, pain, allergies such as eczema and rhinitis, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina, migraine and Reynaud's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, peripheral neuropathy, neuralgia, neuropathological disorders such as Alzheimer's disease, AIDS related dementia, diabetic neuropathy and multiple sclerosis, disorders related to immune enhancement or suppression such as systemic lupus erythematosus, and rheumatic diseases such as fibrosis in a mammal, including a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such condition, and a pharmaceutically acceptable carrier.

The present invention also relates to a method of treating or preventing a condition selected from the group consisting of inflammatory diseases (e.g., arthritis, psoriasis, asthma and inflammatory bowel disease), anxiety, depression or dysthymic disorders, colitis, psychosis, pain, allergies such as eczema and rhinitis, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina, migraine and Reynaud's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, peripheral neuropathy, neuralgia, neuropathological disorders such as Alzheimer's disease, AIDS related dementia, diabetic neuropathy and multiple sclerosis, disorders related to immune enhancement or suppression such as systemic lupus erythematosus, and rheumatic diseases such as fibrosis in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such condition.

The present invention also relates to a pharmaceutical composition for antagonizing the effects of substance P in a mammal, including a human, comprising a substance P antagonizing amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present invention also relates to a method of antagonizing the effects of substance P in a mammal, including a human, comprising administering to said mammal a substance P antagonizing amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.

The present invention also relates to a pharmaceutical composition for treating or preventing a disorder in a mammal, including a human, resulting from an excess of substance P, comprising a substance P antagonizing amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present invention also relates to a method of treating or preventing a disorder in a mammal, including a human, resulting from an excess of substance P, comprising administering to said mammal a substance P antagonizing amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.

The present invention also relates to a pharmaceutical composition for treating or preventing a condition selected from the group consisting of inflammatory diseases (e.g., arthritis, psoriasis, asthma and inflammatory bowel disease), anxiety, depression or dysthymic disorders, colitis, psychosis, pain, allergies such as eczema and rhinitis, 5 chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina, migraine and Reynaud's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, peripheral neuropathy, neuralgia, neuropathological 10 disorders such as Alzheimer's disease, AIDS related dementia, diabetic neuropathy and multiple sclerosis, disorders related to immune enhancement or suppression such as systemic lupus erythematosus, and rheumatic diseases such as fibrosis in a mammal, including a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in antagonizing the effect of 15 substance P at its receptor site, and a pharmaceutically acceptable carrier.

The present invention also relates to a method of treating or preventing a condition selected from the group consisting of inflammatory diseases (e.g., arthritis, psoriasis, asthma and inflammatory bowel disease), anxiety, depression or dysthymic disorders, colitis, psychosis, pain, allergies such as eczema and rhinitis, chronic 20 obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina, migraine and Reynaud's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, peripheral neuropathy, neuralgia, neuropathological 25 disorders such as Alzheimer's disease, AIDS related dementia, diabetic neuropathy and multiple sclerosis, disorders related to immune enhancement or suppression such as systemic lupus erythematosus, and rheumatic diseases such as fibrosis in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in 30 antagonizing the effect of substance P at its receptor site.

The present invention also relates to a pharmaceutical composition for treating or preventing a disorder in a mammal, including a human, the treatment or prevention of which is effected or facilitated by a decrease in substance P mediated

-6-

neurotransmission, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in antagonizing the effect of substance P at its receptor site, and a pharmaceutically acceptable carrier.

The present invention also relates to a method of treating or preventing a disorder in mammal, including a human, the treatment or prevention of which is effected or facilitated by a decrease in substance P mediated neurotransmission, comprising administering to said mammal an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in antagonizing the effect of substance P at its receptor site.

10 The present invention also relates to a pharmaceutical composition for treating or preventing a disorder in a mammal, including a human, the treatment or prevention of which is effected or facilitated by a decrease in substance P mediated neurotransmission, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder, and a pharmaceutically acceptable carrier.

15 The present invention also relates to a method of treating or preventing a disorder in mammal, including a human, the treatment or prevention of which is effected or facilitated by a decrease in substance P mediated neurotransmission, comprising administering to said mammal an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder.

20 The compounds of the formula I have chiral centers and therefore exist in different enantiomeric forms. This invention relates to all optical isomers and all stereoisomers of compounds of the formula I, and mixtures thereof.

25 Optically active compounds of the formula I are additionally useful as synthetic intermediates in the preparation of the corresponding racemic mixtures and opposite enantiomers.

30 Formulae I and VII above include compounds identical to those depicted but for the fact that one or more hydrogen or carbon atoms are replaced by radioactive isotopes thereof (e.g., tritium, nitrogen-15 or carbon-13 isotopes thereof). Such radiolabelled compounds are useful as research and diagnostic tools in metabolism pharmacokinetic studies and in binding assays. Specific applications in research include radioligand binding assays, autoradiography studies and in vivo binding studies, while

-7-


specific applications in the diagnostic area include studies of the substance P receptor in the human brain in in vivo binding in the relevant tissues for inflammation, e.g. immune-type cells or cells that are directly involved in inflammatory bowel disorders and the like.

5

Detailed Description of the Invention


The compounds of the formula I may be prepared as described in the following reaction scheme and discussion. Unless otherwise indicated, in the reaction scheme and discussion that follow, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are defined as above.

-8-

Scheme 1

-9-

Scheme 2



-10-

5 Referring to scheme , N-carboethoxyperhydroazepin-4-one (II) is reacted with tosylmethylisocyanide in an inert solvent such as glyme or another ethereal solvent, or a protic, apolar solvent such as dimethylsulfoxide, in the presence of a base such as an alkali metal alkoxide, for about 10 minutes to 24 hours. Preferably, the solvent is glyme and the reaction is carried out in the presence of ethanol and potassium t-  
10 butoxide for about 18 hours. This reaction is generally conducted at a temperature from about -50°C to about the reflux temperature of the solvent, and is preferably conducted at about 60°C.

The foregoing reaction produces the compound 4-cyano-N-carboethoxyperhydroazepine (III), which is then converted to ethylperhydroazepine-4-carboxylate (IV) by reacting it with a mineral acid, sulfuric acid or phosphoric acid, preferably hydrochloric acid. Generally, this reaction is conducted in a lower alcohol solvent, preferably ethanol, at a temperature from about room temperature to about the reflux temperature of the solvent, preferably at the reflux temperature of the solvent, for about 10 minutes to about 24 hours, preferably about 18 hours.

20 Treatment of ethyl perhydroazepine-4-carboxylate (IV) with an alkanoylmethyl halide, preferably ethylbromoacetate, in the presence of a soluble organic base such as a tertiary alkyl amine (e.g., triethylamine), produces ethyl-N-ethoxycarbonylmethylperhydroazepine-4-carboxylate (V). Suitable solvents for this reaction include lower alcohols, with ethanol being preferred. The reaction temperature may range from about room temperature to about the reflux temperature of the solvent, and is preferably the reflux temperature of the solvent. This reaction is usually carried out for about 10 minutes to 100 hours, preferably about 18 hours.


The ethyl-N-ethoxycarbonylmethylperhydroazepine-4-carboxylate (V) obtained in the above step is then converted to 1-azabicyclo[3.2.2]nonan-3-one (VI) by reacting 30 it with an alkali or alkaline earth metal alkoxide, preferably potassium ethoxide. Suitable reaction inert solvents for this reaction include hydrocarbon solvents such as hexane, benzene and toluene. Suitable reaction temperatures range from about room temperature to about the reflux temperature of the solvent. The reflux temperature is preferred. The solvent is then evaporated and the residue taken up in a mineral acid 35 such as dilute hydrochloric or dilute sulfuric acid. An ethereal hydrocarbon solvent such as dioxane may optionally be used as a co-solvent. Preferably, this reaction is

-11-

conducted at the reflux temperature of the solvent, but temperatures ranging from about room temperature to about the reflux temperature are also suitable.

The desired compound of the formula VII is obtained by treating 1-azabicyclo[3.2.2]nonan-3-one with the appropriate compound of the formula

5



10

This reaction is typically carried out in a reaction inert aqueous or organic solvent. Suitable solvents include water, lower alcohols, ether, tetrahydrofuran (THF), dimethylformamide (DMF), benzene, toluene, hexane, methylene chloride and chloroform. Ethanol is the preferred solvent. Preferably, the reaction is run in the presence of a basic catalyst. Sodium hydroxide is the preferred catalyst, but other bases such as alkali and alkaline earth metal hydroxides, carbonates and alkoxides, as well as organic amine bases such as trialkylamines and pyridine may also be used. Generally, the reaction is run for about 10 minutes to about 24 hours. The reaction temperature may range from about 0°C to about 200°C, and is preferably about the reflux temperature of the solvent.


The compound of formula VII so obtained is then reacted with a compound of the formula  $(R^3)(R^4)C_6H_5MgX$  wherein X is chloro, fluoro, bromo or iodo, to form a compound of the formula VIII. This reaction is usually carried out in a reaction inert hydrocarbon, chlorohydrocarbon or ethereal solvent such as benzene, ether, toluene, hexane, THF or ethyl acetate. The preferred solvent is ether. The reaction is usually run for about 1 minute to about 10 hours. Suitable reaction temperatures range from about -70°C to about 100°C, with about 0°C being preferred.

The compound of formula VIII is then converted to the corresponding desired compound of the formula I by reacting it with a compound of the formula

30

-12-

5



and then treating the reaction mixture with a reducing agent.

The reaction of the compound of formula VIII with the above amine of formula IX is typically carried out in a reaction inert hydrocarbon or chlorohydrocarbon solvent 10 in the presence of an acidic catalyst. Examples of solvents that may be used include hexane, benzene, toluene, chloroform, methylene chloride, ether, THF, and ethyl acetate. Examples of catalysts that may be used include mineral acids, titanium trichloride, molecular sieves and organic acids such as camphor sulfonic acid. Toluene is the preferred solvent and camphor sulfonic acid is the preferred catalyst. This 15 reaction is generally conducted over a period of about 0.5 hours to about 24 hours, at a temperature from about room temperature is about 110°C. The reflux temperature of the solvent is preferred.

The reaction mixture is then treated with a reducing agent, as indicated above, to obtain the desired compound of formula I. Reducing agents that may be used 20 include 9-borabicyclononane (9-BBN), triethylsilane and metal hydrides such as sodium borohydride and sodium triacetoxyborohydride. The preferred reducing agent is 9-BBN. Generally, the reduction is carried out in a reaction inert hydrocarbon, chlorohydrocarbon, carboxyhydrocarbon, aqueous or alcoholic solvent. Water, lower alcohols, trifluoroacetic acid, benzene, toluene, ether, hexane, THF, ethyl acetate and 25 chloroform are suitable, with THF being preferred when the reducing agent is 9-BBN. The preferred reaction temperature is about room temperature, but the reduction may be carried out at temperatures ranging from about room temperature to about 200°C.

The 2R,3R enantiomers of the compounds of formula I may be converted into the corresponding 2S,3S enantiomers by the following procedure, which is illustrated 30 in Scheme 2.

Referring to scheme 2, the 2R,3R enantiomer having the formula I-A is treated with hydrogen in the presence of a metal containing catalyst such as platinum or palladium. Generally, this reaction is conducted in a reaction inert solvent such as

acetic acid or a lower alcohol, at a temperature from about 0°C to about 50°C. Preferably, the compound of formula I-A is treated with hydrogen in the presence of palladium on carbon in a mixture of methanol/ethanol in water or methanol/ethanol containing hydrochloric acid at a temperature of about 25°C.

5       The above reaction yields an amine having the formula X. This amine is then reacted with a compound of the formula R<sup>1</sup>CHO in the presence of a drying agent or using an apparatus designed to remove azeotropically the water generated, to produce an imine of the formula XI. The preparation of the imine is generally carried out in a reaction inert solvent such as benzene, xylene or toluene, preferably toluene, at a  
10      temperature from about 25°C to about 110°C, preferably at about the reflux temperature of the solvent. Suitable drying agents/solvent systems include titanium tetrachloride/dichloromethane, titanium isopropoxide/dichloromethane and molecular sieves/THF. Titanium tetrachloride/dichloromethane is preferred.

15      The resulting imine of formula XI is then converted to the corresponding isomeric imine having the formula XII by reacting it with a strong base such as lithium diisopropylamide or t-butyl lithium. An equilibrium between the imines of formulae XI and XII results. This reaction is typically conducted in an ethereal solvent such as THF or ethyl ether, at a temperature from about -78°C to about the reflux temperature of the solvent. It is preferably conducted at the reflux temperature. Hydrolysis of the imine  
20      of formula XII yields the corresponding ketone having the formula VIII-A. The hydrolysis is preferably conducted using a mineral acid such as hydrochloric or sulfuric acid, at a temperature from about 0°C to about 100°C.

25      The ketone of formula VIII-A formula in the preceding step may be converted to the corresponding 2S, 3S enantiomer of formula I-B by the procedure described above and depicted in scheme 1 for converting compounds of the formula VIII into compounds of the formula I.

30      In each of the reactions discussed or illustrated in schemes 1 to 4 above, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure, i.e. about 1 atmosphere, is preferred as a matter of convenience.

35      The novel compounds of the formula I and the pharmaceutically acceptable salts thereof are useful as substance P antagonists, i.e., they possess the ability to antagonize the effects of substance P at its receptor site in mammals, and therefore

they are able to function as therapeutic agents in the treatment of the aforementioned disorders and diseases in an afflicted mammal.

The compounds of the formula I which are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids.

- 5 Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the Formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained.
- 10
- 15 The compounds of Formula I and their pharmaceutically acceptable salts exhibit substance P receptor-binding activity and therefore are of value in the treatment and prevention of a wide variety of clinical conditions the treatment or prevention of which are effected or facilitated by a decrease in substance P mediated neurotransmission. Such conditions include inflammatory diseases (e.g., arthritis, psoriasis, asthma and
- 20 inflammatory bowel disease), anxiety, depression or dysthymic disorders, colitis, psychosis, pain, allergies such as eczema and rhinitis, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina, migraine and Reynaud's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as
- 25 shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, peripheral neuropathy, neuralgia, neuropathological disorders such as Alzheimer's disease, AIDS related dementia, diabetic neuropathy and multiple sclerosis, disorders related to immune enhancement or suppression such as systemic lupus erythematosus, and rheumatic diseases such as fibrosis. Hence, these
- 30 compounds are readily adapted to therapeutic use as substance P antagonists for the control and/or treatment of any of the aforesaid clinical conditions in mammals, including humans.

-15-

The compounds of the formula I and the pharmaceutically acceptable salts thereof can be administered via either the oral, parenteral or topical routes. In general, these compounds are most desirably administered in dosages ranging from about 5.0 mg up to about 1500 mg per day, although variations will necessarily occur depending upon the weight and condition of the subject being treated and the particular route of administration chosen. However, a dosage level that is in the range of about 0.07 mg to about 21 mg per kg of body weight per day is most desirably employed. Variations may nevertheless occur depending upon the species of animal being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.

15       The compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by either of the three routes previously indicated, and such administration may be carried out in single or multiple doses. More particularly, the novel therapeutic agents of this invention can be administered in a wide variety of different dosage forms, i.e., they may be combined 20 with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, oral pharmaceutical 25 compositions can be suitably sweetened and/or flavored. In general, the therapeutically-effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.

For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and 30 glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and

talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral 5 administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

For parenteral administration, solutions of a therapeutic compound of the 10 present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation 15 of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

Additionally, it is also possible to administer the compounds of the present 20 invention topically when treating inflammatory conditions of the skin and this may preferably be done by way of creams, jellies, gels, pastes, ointments and the like, in accordance with standard pharmaceutical practice.

The activity of the compounds of the present invention as substance P antagonists is determined by their ability to inhibit the binding of substance P at its receptor sites in bovine caudate tissue, employing radioactive ligands to visualize the tachykinin receptors by means of autoradiography. The substance P antagonizing 25 activity of the herein described compounds may be evaluated by using the standard assay procedure described by M. A. Cascieri et al., as reported in the Journal of Biological Chemistry, Vol. 258, p. 5158 (1983). This method essentially involves determining the concentration of the individual compound required to reduce by 50% the amount of radiolabelled substance P ligands at their receptor sites in said isolated 30 cow tissues, thereby affording characteristic IC<sub>50</sub> values for each compound tested.

In this procedure, bovine caudate tissue is removed from a -70°C freezer and homogenized in 50 volumes (w/v.) of an ice-cold 50 mM Tris (i.e., trimethylamine which is 2-amino-2-hydroxymethyl-1,3-propanediol) hydrochloride buffer having a pH of 7.7.

The homogenate is centrifuged at 30,000 x G for a period of 20 minutes. The pellet is resuspended in 50 volumes of Tris buffer, rehomogenized and then recentrifuged at 30,000 x G for another twenty- minute period. The pellet is then resuspended in 40 volumes of ice-cold 50 mM Tris buffer (pH 7.7) containing 2 mM of calcium chloride, 5 2 mM of magnesium chloride, 40 g/ml of bacitracin, 4 $\mu$ g/ml of leupeptin, 2 $\mu$ g of chymostatin and 200 g/ml of bovine serum albumin. This step completes the production of the tissue preparation.

The radioligand binding procedure is then carried out in the following manner, viz., by initiating the reaction via the addition of 100  $\mu$ l of the test compound made up 10 to a concentration of 1  $\mu$ M, followed by the addition of 100  $\mu$ l of radioactive ligand made up to a final concentration 0.5 mM and then finally by the addition of 800  $\mu$ l of the tissue preparation produced as described above. The final volume is thus 1.0 ml, and the reaction mixture is next vortexed and incubated at room temperature (ca. 20°C) for a period of 20 minutes. The tubes are then filtered using a cell harvester, and the 15 glass fiber filters (Whatman GF/B) are washed four times with 50 mM of Tris buffer (pH 7.7), with the filters having previously been presoaked for a period of two hours prior to the filtering procedure. Radioactivity is then determined in a Beta counter at 53% counting efficiency, and the IC<sub>50</sub> values are calculated by using standard statistical methods.

20 The anti-psychotic activity of the compounds of the present invention as neuroleptic agents for the control of various psychotic disorders is determined primarily by a study of their ability to suppress substance P-induced or substance P agonist induced hypermotility in guinea pigs. This study is carried out by first dosing the guinea pigs with a control compound or with an appropriate test compound of the present 25 invention, then injecting the guinea pigs with substance P or a substance P agonist by intracerebral administration via canula and thereafter measuring their individual locomotor response to said stimulus.

The anti-inflammatory activity of the compounds of the present invention is demonstrated in the standard carrageenin-induced rat foot edema test [described by 30 C>A> Winter et al., Proceedings of the Society of Experimental Biology and Medicine, Vol. 111, p. 544 (1962)]. In this test, anti-inflammatory activity is determined as the percent inhibition of edema formation in the hind paw of male albino rats (weighing 150-190 g) in response to a sub-plantar injection of carrageenin. The carrageenin is

-18-

injected as a 1% aqueous solution. Edema formation is then assessed by measuring the volume of the injected paw initially as well as three hours after the carrageenin injection. The increase in volume three hours after carrageenin injection constitutes the individual response. Compounds are considered active if the difference in response  
5 between the drug-treated animals (six rats/group) and a control group receiving the vehicle alone is significant on comparison with the results afforded by a standard compound like phenylbutazone at 33 mg/kg, via the oral route of administration.

The present invention is illustrated by the following examples. It will be understood, however, that the invention is not limited to the specific details of these  
10 examples.

#### EXAMPLE 1

##### 2-(Diphenylmethyl)-N-((2-methoxyphenyl)methyl)-1-azabicyclo[3.2.2]nonan-3-amine

###### A. 4-Cyano-N-carboethoxyperhydroazepine

To a 250 mL round-bottomed flask equipped with condenser and nitrogen inlet were added 4.34 g (23.49 mmol) N-carboethoxyperhydroazepin-4-one (prepared according to the procedure given by Z.G. Finney and T.N. Riley, J. Med. Chem., **23**, 895 (1980)), 10.53 g (54.02 mmol) tosylmethylisocyanide, and 117 mL 1,2-dimethoxyethane. The solution was cooled to 0°C, and 2.48 mL (54.02 mmol) ethanol  
15 and 9.21 g (82.2 mmol) potassium t-butoxide were added. The mixture was heated at 60°C for 18 hours, cooled, and evaporated. The residue was taken up in ethyl acetate, washed with brine, dried over sodium sulfate, and concentrated to an oil. The oil was purified by chromatography on silica gel using hexane/ethyl acetate as eluent to afford  
20 4.6 g (100%) of an oil.

<sup>1</sup>H-NMR ( $\delta$ , CDCl<sub>3</sub>): 1.14 (t, J=5, 6H), 1.8-2.0 (m, 6H), 2.74 (m, 1H), 3.2-3.5 (m, 4H), 4.02 (quartets, J=5, 4H).

IR (cm<sup>-1</sup>, KBr): 2225 (CN), 1695 (CO).

<sup>13</sup>C-NMR ( $\delta$ , CDCl<sub>3</sub>): 14.7, 25.2, 25.4, 29.1, 29.3, 29.4, 29.5, 31.7, 31.9, 43.3, 43.7, 45.7, 61.3, 121.6, 155.9, 156.0.

MS (%): 196 (53, parent), 123 (100), 56 (39).

Anal. Calc'd. for C<sub>10</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>: C 61.20, H 8.22, N 14.27. Found: C 61.15, H 8.51, N 14.27.

**B. Ethylperhydroazepine-4-carboxylate**

To a 250 mL round-bottomed flask equipped with condenser and nitrogen inlet were added 4.6 g (23.5 mmol) 4-cyano-N-carboethoxyperhydroazepin-4-one and 100 mL 6N hydrochloric acid. The mixture was refluxed 18 hours, cooled, and 5 evaporated. The residue was taken up in 100 mL ethanol, saturated with hydrogen chloride gas and refluxed 36 hours. The reaction was cooled and evaporated, and the product characterized by mass spectrum before proceeding directly to the next step.

MS (%): 171 (11, parent), 101 (62), 86 (100), 56 (71).

**C. Ethyl-N-ethoxycarbonylmethyl-perhydroazepine-4-carboxylate**

10 The above compound (23.5 mmol) was dissolved in 120 mL ethanol, treated with 7.16 g (70.88 mmol) triethylamine and 5.92 g (35.44 mmol) ethyl bromoacetate, and refluxed for 2 hours. The reaction was cooled, evaporated, taken up in methylene chloride, washed with saturated aqueous sodium bicarbonate solution, dried over sodium sulfate and evaporated. The residue was chromatographed on silica gel using 15 hexane/ethyl acetate as eluent to afford an oil, 4.17 g (69%).

<sup>1</sup>H NMR ( $\delta$ , CDCl<sub>3</sub>): 1.13 (t, J=6, 3H), 1.15 (t, J=6, 3H), 1.5-1.9 (m, 6H), 2.48 (m, 1H), 2.6-2.8 (m, 4H), 3.25 (m, 2H), 4.04 (quartets, 4H).

IR (cm<sup>-1</sup>, KBr): 1735 (CO).

<sup>13</sup>C-NMR ( $\delta$ , CDCl<sub>3</sub>): 14.1, 14.2, 26.9, 29.5, 30.9, 43.6, 52.7, 54.9, 59.5, 60.0, 20 60.2, 171.3, 176.2.

MS (%): 257 (4, parent), 212 (10), 185 (16), 184 (100).

Anal. Calc'd. for C<sub>13</sub>H<sub>23</sub>NO<sub>4</sub>: C 60.68, H 9.01, N 5.44. Found: C 60.22, H 9.12, N 5.57.

**D. 1-Azabicyclo[3.2.2]nonan-3-one**

25 To a 250 mL round-bottomed flask equipped with condenser and nitrogen inlet were added 1.55 g (39.69 g-atm.) potassium and 80 mL toluene. The mixture was heated to reflux and treated with 1.83 mL (39.69 mmol) ethanol. Refluxing continued until the potassium disappeared. Then 4.08 g (15.87 mmol) ethyl-N-ethoxycarbonylmethyl-perhydroazepine-4-carboxylate was added and refluxing was 30 continued for 14 hours. The reaction was evaporated and the residue taken up in 100 mL 1N hydrochloric acid. This solution was refluxed for 22 hours, cooled, washed with methylene chloride, and adjusted to pH 12 with 6N sodium hydroxide. The aqueous

-20-

layer was extracted with methylene chloride, which was dried over sodium sulfate and evaporated. The resulting foam, 700 mg (32%), was used directly below.

E. 2-(Phenylmethylen)-1-azabicyclo[3.2.2]nonan-3-one

To a 50 mL round-bottomed flask equipped with condenser and nitrogen inlet were added the title compound from step D (5.04 mmol), 40 mg (1.01 mmol) sodium hydroxide, 800 mg (7.55 mmol) benzaldehyde, and 13 mL ethanol. The solution was refluxed for 30 minutes, cooled, and evaporated. The residue was dissolved in methylene chloride, washed with water and brine, dried over sodium sulfate and evaporated. The residue was chromatographed on silica gel using hexane/ethyl acetate as eluent to afford an oil, 1.02 g (89%).

<sup>1</sup>H-NMR ( $\delta$ , CDCl<sub>3</sub>): 1.5-1.7 (m, 1H), 1.75 (m, 2H), 1.8-2.0 (m, 2H), 2.1-2.2 (m, 1H), 2.73 (m, 1H), 2.9-3.1 (m, 3H), 3.2-3.3 (m, 1H), 7.01 (s, 1H), 7.2-7.4 (m, 3H), 7.9 (m, 2H).

IR (cm<sup>-1</sup>, KBr): 1705 (CO) and 1620 (C=C).

<sup>13</sup>C-NMR ( $\delta$ , CDCl<sub>3</sub>): 24.4, 26.5, 28.6, 44.6, 45.0, 56.3, 125.4, 128.5, 129.2, 131.4, 134.2, 145.8, 204.6.

MS (%): 227 (100, parent), 171 (86), 170 (81), 55 (54).

Anal. Calc'd. for C<sub>15</sub>H<sub>17</sub>NO•0.25H<sub>2</sub>O: C 77.72, H 7.61, N 6.04. Found: C 77.90, H 7.36, N 5.99.

F. 2-(Diphenylmethyl)-1-azabicyclo[3.2.2]nonan-3-one

To a 100 mL round-bottomed flask equipped with nitrogen inlet were added 2 mL (5.84 mmol) of a 3 M solution of phenylmagnesium bromide in ether and 35 mL toluene. The solution was cooled to 0°C, and a solution of 1.02 g (4.49 mmol) 2-(phenylmethylen)-1-azabicyclo[3.2.2]nonane-3-one in 10 mL toluene was added. The reaction was stirred at 0°C for 1 hour and quenched with saturated aqueous ammonium chloride. The organic layer was diluted with ethyl acetate, washed with saturated aqueous ammonium chloride solution until it was clear, dried over sodium sulfate, and evaporated. The residue was chromatographed on silica gel using hexane/ethyl acetate as eluent to afford an oil, 209 mg (16%, the 1,2 addition product accounted for about 40% of the reaction).

<sup>1</sup>H-NMR ( $\delta$ , CDCl<sub>3</sub>): 1.5-2.0 (m, 6H), 2.64 (m, 2H), 2.6-2.8 (m, 1H), 3.0-3.2 (m, 2H), 3.93 (d, J=8, 1H), 4.47 (d, J=8, 1H), 7.0-7.4 (m, 10H).

IR (cm<sup>-1</sup>, KBr): 1720 (CO).

-21-

<sup>13</sup>C-NMR ( $\delta$ , CDCl<sub>3</sub>): 24.1, 24.7, 26.0, 29.4, 30.0, 41.3, 46.0, 46.5, 48.0, 49.7, 50.6, 51.5, 58.9, 70.2, 72.7, 126.5, 128.1, 128.3, 128.4, 128.5, 128.7, 142.2, 142.7.

MS (%): 305 (3, parent), 277 (100), 110 (94), 91 (47).

HRMS: Calc'd. for C<sub>21</sub>H<sub>23</sub>NO: 305.1779. Found: 305.1767.

5        G.     2-(Diphenylmethyl)-N-((2-methoxyphenyl)methyl)-1-azabicyclo[3.2.2]-nonan-3-amine

To a 20 mL round-bottomed flask equipped with condenser and nitrogen inlet were added 209 mg (0.685 mmol) 2-(diphenylmethyl)-1-azabicyclo[3.2.2]nonan-3-one, 141 mg (1.03 mmol) 2-methoxybenzylamine, 2 mg camphorsulfonic acid, 3 Å molecular 10 sieves, and 4 mL toluene. The solution was refluxed for 22 hours, cooled, decanted from the sieves and evaporated. The residue was taken up in 0.5 mL tetrahydrofuran and treated with 2.7 mL (1.37 mmol) of a 0.5 M solution of 9-borabicyclo[3.3.1]nonane in tetrahydrofuran and stirred at room temperature for 7 days. The reaction mixture was taken up in methylene chloride, washed with 1N hydrochloric acid, and the aqueous 15 layer adjusted to pH 12 with 6N aqueous sodium hydroxide and extracted with methylene chloride. The organic layer was dried over sodium sulfate, evaporated, and chromatographed on silica gel using methanol/methylene chloride as eluent to afford an oil, which was converted to its hydrochloride salt using HCl in ether, affording a white solid, mp 170-190°C, 29 mg (8%).

20        <sup>1</sup>H-NMR ( $\delta$ , CDCl<sub>3</sub>): 1.5-1.7 (m, 3H), 1.7-1.9 (m, 3H), 2.21 (m, 1H), 2.6 (m, 1H), 2.7 (m, 1H), 2.84 (m, 1H), 2.95 (m, 1H), 3.2 and 3.6 (m, 2H), 3.25 (m, 1H), 3.63 (s, 3H), 3.94 (dd, J=7.7,11.3, 1H), 4.34 (d, J=11.3, 1H), 6.6-7.4 (m, 14H).

IR (cm<sup>-1</sup>, KBr): 1620 (C=C).

25        <sup>13</sup>C-NMR ( $\delta$ , CDCl<sub>3</sub>): 21.7, 25.2, 25.4, 28.9, 30.0, 41.8, 46.3, 51.3, 55.3, 57.4, 59.5, 63.9, 110.1, 120.3, 125.5, 126.1, 127.7, 127.96, 127.04, 128.2, 128.34, 128.37, 128.42, 128.47, 128.52, 128.6, 128.8, 129.00, 129.07, 129.14, 129.6, 129.7, 143.0, 145.8, 157.3.

MS (%): 427 (2, parent+1), 260 (39), 259 (100), 121 (74), 110 (41), 91 (55).

Anal. Calc'd. for C<sub>29</sub>H<sub>34</sub>N<sub>2</sub>O•2HCl•H<sub>2</sub>O: C 67.30, H 7.40, N 5.41. Found: C 30 67.11, H 7.21, N 5.18.

The title compounds of Examples 2-4 were prepared by a procedure analogous to that described in Example 1.

-22-

EXAMPLE 2

2-(Diphenylmethyl)-N-((2-chlorophenyl)methyl)-1-azabicyclo[3.2.2.]nonan-3-amine

The title compound was prepared in 12% yield, as a dihydrochloride salt, mp 214-218°C.

5       <sup>1</sup>H-NMR ( $\delta$ , CDCl<sub>3</sub>): 1.3-2.0 (m, 6H), 2.39 (m, 1H), 2.59 (m, 1H), 2.70 (m, 1H), 2.85 (m, 1H), 2.96 (m, 1H), 3.23 (m, 1H), 3.41 (dd, J=12, 134, 2H), 3.99 (m, 1H), 4.29 (d, J=10, 1H), 6.57 and 7.0-7.4 (m, 14H).

IR (cm.<sup>-1</sup>, KBr): 1695, 1560 (C=C).

10      <sup>13</sup>C-NMR ( $\delta$ , CDCl<sub>3</sub>): 21.8, 25.2, 28.8, 30.2, 41.9, 49.5, 51.4, 57.8, 59.5, 64.0, 125.5, 126.3, 126.6, 127.8, 127.9, 128.0, 128.9, 129.2, 130.1, 133.7, 137.7, 143.0, 145.6. MS (%): 431 (1, parent), 265 (50), 263 (96), 140 (100), 125 (62), 110 (58).

Anal. Calc'd. for C<sub>28</sub>H<sub>31</sub>N<sub>2</sub>Cl•2HCl•2.5H<sub>2</sub>O: C 61.26, H 6.98, N 5.10. Found: C 61.06, H 6.76, N 4.20.

EXAMPLE 3

2-(Diphenylmethyl)-N-((2,4-dimethoxyphenyl)methyl)-1-azabicyclo[3.2.2]nonan-3-amine

The title compound was prepared in 10% yield, as a dihydrochloride salt, mp 230-245°C.

15      <sup>1</sup>H-NMR ( $\delta$ , CDCl<sub>3</sub>): 1.5-2.0 (m, 6H), 2.42 (m, 1H), 2.60 (m, 1H), 2.69 (m, 1H), 2.84 (m, 1H), 2.95 (m, 1H), 3.25 (m, 1H), 3.31 (dd, J=13,126, 2H), 3.61 (s, 3H), 3.79 (s, 3H), 3.95 (dd, J=7,12, 1H), 4.37 (d, J=12, 1H), 6.3, 6.5 and 7.0-7.4 (m, 13H).

IR (cm.<sup>-1</sup>, KBr): 1620, 1590, 1570 (C=C).

20      <sup>13</sup>C-NMR ( $\delta$ , CDCl<sub>3</sub>): 21.8, 25.3, 29.0, 30.0, 41.8, 51.3, 55.3, 55.4, 57.4, 59.5, 63.8, 103.8, 125.4, 126.1, 127.8, 128.0, 128.1, 128.8, 130.2, 143.0, 145.9, 158.3, 159.7. 25      Anal. Calc'd. for C<sub>30</sub>H<sub>36</sub>N<sub>2</sub>O<sub>2</sub>•2HCl•3.5H<sub>2</sub>O: C 61.27, H 7.63, N 4.76. Found: C 61.20, H 7.45, N 4.63.

EXAMPLE 4

2-(Bis(4-fluorophenyl)methyl)-N-((2-methoxyphenyl)methyl)-1-azabicyclo[3.2.2]-nonan-3-amine

30      The title compound was prepared in 12% yield, as a dihydrochloride salt, mp 170-180°C.

-23-

<sup>1</sup>H-NMR ( $\delta$ , CDCl<sub>3</sub>): 1.4-2.0 (m, 6H), 2.40 (m, 1H), 2.45 (m, 1H), 2.63 (m, 1H), 2.76 (m, 1H), 2.84 (m, 1H), 3.10 (m, 1H), 3.31 (dd, J=13,130, 2H), 3.62 (s, 3H), 3.71 (dd, J=7,12, 1H), 6.6-7.2 (m, 12H).

IR (cm.<sup>-1</sup>, KBr): 1610 (C=C).

5 <sup>13</sup>C-NMR ( $\delta$ , CDCl<sub>3</sub>): 21.7, 25.2, 28.9, 30.0, 41.7, 46.7, 49.6, 55.2, 57.2, 59.5, 64.4, 110.1, 114.5, 114.8, 115.3, 115.6, 120.2, 128.0, 128.3, 129.3, 129.4, 129.6, 129.7, 138.68, 138.72, 141.4, 157.4, 159.6, 162.5, 162.9.

Anal. Calc'd. for C<sub>28</sub>H<sub>32</sub>N<sub>2</sub>OF<sub>2</sub>•2HCl•1.5H<sub>2</sub>O: C 61.92, H 6.63, N 4.98. Found: C 61.86, H 6.91, N 4.89.

10

#### EXAMPLE 5

##### 2-((4-Fluorophenyl)methylene)-1-azabicyclo[3.2.2]nonan-3-one

The title compound was prepared by a procedure analogous to that described in Example 1E in 98% yield, as a yellow oil.

15 <sup>1</sup>H-NMR ( $\delta$ , CDCl<sub>3</sub>): 1.5-2.3 (m, 6H), 2.77 (m, 1H), 2.9-3.3 (m, 4H), 6.9-7.1 and 7.8-8.0 (m, 4H), 7.24 (s, 1H).

IR (cm.<sup>-1</sup>, KBr): 1700 (C=O).

MS (%): 245 (100, parent), 216 (75), 189 (83), 188 (74), 121 (38), 55 (43).

High Res. MS: Calc'd. for C<sub>15</sub>H<sub>16</sub>NOF: 245.1197. Found: 245:1222.

#### EXAMPLE 6

20

##### 2-((Bis-(4-fluorophenyl)methyl)-1-azabicyclo[3.2.2]nonane-3-one

The title compound was prepared by a procedure analogous to that described in Example 1F.

15 <sup>1</sup>H-NMR ( $\delta$ , CDCl<sub>3</sub>): 1.6-2.1 (m, 6H), 2.6-2.7 (m, 3H), 3.1-3.3 (m, 2H), 3.95 (d, J=9, 1H), 4.49 (d, J=9, 1H), 6.9-7.0 and 7.2-7.4 (m, 8H).

25

IR (cm.<sup>-1</sup>), KBr: 1705 (C=O).

15 <sup>13</sup>C-NMR ( $\delta$ , CDCl<sub>3</sub>): 24.0, 26.1, 29.2, 41.4, 46.5, 49.6, 59.0, 70.3, 115.0, 115.2, 115.3, 129.8, 130.0, 130.1, 137.7, 137.8, 138.4, 138.5, 159.9, 160.0, 163.1, 163.2, 216.5.

MS (%): 341 (1, parent), 313 (62), 110 (100), 109 (56), 82 (46).

30

Anal. Calc'd. for C<sub>21</sub>H<sub>21</sub>NOF<sub>2</sub>: C 73.88, H 6.20, N 4.10. Found: C 74.04, H 6.12, N 4.10.


-24-

CLAIMS

## 1. A compound of the formula

5

10



wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each independently selected from hydrogen, fluorine, chlorine, bromine, trifluoromethyl, alkyl having from one to three carbon atoms, 15 alkoxy having from one to three carbon atoms, carboxy, alkoxy carbonyl having from one to three carbon atoms in the alkoxy moiety and benzoyloxycarbonyl; or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein R<sup>1</sup> is methoxy and each of R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> is hydrogen.

20 3. A compound according to claim 2 wherein R<sup>1</sup> is 2-methoxy.

4. A pharmaceutical composition for treating or preventing a condition selected from the group consisting of inflammatory diseases, anxiety, colitis, depression or dysthymic disorders, psychosis, pain, allergies, chronic obstructive airways disease, hypersensitivity disorders, vasospastic diseases, fibrosing and collagen diseases, reflex 25 sympathetic dystrophy, addiction disorders, stress related somatic disorders, peripheral neuropathy, neuralgia, neuropathological disorders, disorders related to immune enhancement or suppression and rheumatic diseases in a mammal, comprising an amount of a compound according to claim 1 effective in preventing or treating such condition and a pharmaceutically acceptable carrier.

30 5. A method of treating or preventing a condition selected from the group consisting of inflammatory diseases anxiety, colitis, depression or dysthymic disorders, psychosis, pain, allergies, chronic obstructive airways disease, hypersensitivity disorders, vasospastic diseases, fibrosing and collagen diseases, reflex sympathetic

dystrophy, addiction disorders, stress related somatic disorders, peripheral neuropathy, neuralgia, neuropathological disorders, disorders related to immune enhancement or suppression and rheumatic diseases in a mammal, comprising administering to a mammal in need of such treatment or prevention an amount of a compound according  
5 to claim 1 effective in preventing or treating such condition.

6. A pharmaceutical composition for antagonizing the effects of substance P in a mammal, comprising a substance P antagonizing effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

7. A method of antagonizing the effects of substance P in a mammal,  
10 comprising administering to said mammal a substance P antagonizing effective amount of a compound according to claim 1.

8. A pharmaceutical composition for treating or preventing a condition in a mammal, the treatment or prevention of which is effected or facilitated by a decrease in substance P mediated neurotransmission, comprising an amount of a compound  
15 according to claim 1 effective in antagonizing the effect of substance P at its receptor site and a pharmaceutically acceptable carrier.

9. A method of treating or preventing a condition in a mammal, the treatment or prevention of which is effected or facilitated by a decrease in substance P mediated neurotransmission, comprising administering to a mammal in need of such  
20 treatment or prevention an amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, effective in antagonizing the effect of substance P at its receptor site.


10. A pharmaceutical composition for treating or preventing a condition in a mammal, the treatment or prevention of which is effected or facilitated by a decrease in substance P mediated neurotransmission, comprising an amount of a compound  
25 according to claim 1, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such condition and a pharmaceutically acceptable carrier.

11. A method of treating or preventing a condition in mammal, the treatment or prevention of which is effected or facilitated by a decrease in substance P mediated  
30 neurotransmission, comprising administering to a mammal in need of such treatment or prevention an amount of a compound according to claim 1 effective in treating or preventing such condition.

-26-

## 12. A process for preparing a compound of the formula

5




wherein R<sup>1</sup> is cycloalkyl having from five to seven carbon atoms, pyrrolyl, thienyl, pyridyl, phenyl or substituted phenyl, wherein said substituted phenyl is substituted with  
 10 from one to three substituents independently selected from fluorine, chlorine, bromine, trifluoromethyl, alkyl having from one to three carbon atoms, alkoxy having from one to three carbon atoms, carboxy, alkoxycarbonyl having from one to three carbon atoms in the alkoxy moiety and benzyloxycarbonyl;

R<sup>2</sup> is furyl, thienyl, pyridyl, indolyl, biphenyl, phenyl or substituted phenyl,  
 15 wherein said substituted phenyl is substituted with one or two substituents independently selected from fluorine, chlorine, bromine, trifluoromethyl, alkyl having from one to three carbon atoms, alkoxy having from one to three carbon atoms, carboxy, alkoxycarbonyl having from one to three carbon atoms in the alkoxy moiety and benzyloxycarbonyl; and

20 R<sup>3</sup> is thienyl, phenyl, fluorophenyl, chlorophenyl or bromophenyl;  
 or a pharmaceutically acceptable salt thereof,  
 comprising reacting a compound of the formula

25




30

-27-

with a compound of the formula

5




and then reacting the reaction mixture with a reducing agent.

13. A process according to claim 12, wherein said reducing agent reducing  
10 is 9-borabicyclononane, triethyl silane or a metal hydride.

14. A process according to claim 12, wherein said compound of formula VIII  
is obtained by reacting a compound of the formula

15



20

VII

with a compound of the formula  $(R^3)(R^4)C_6H_5MgX$  wherein  $R^3$  and  $R^4$  are defined as in claim 12 and X is chloro, fluoro, bromo or iodo.

15. A process according to any of claims 12-14, wherein said process  
25 produces a compound of the formula I wherein  $R^1$  is methoxy and each of  $R^2$ ,  $R^3$ ,  $R^4$ ,  
 $R^5$  and  $R^6$  is hydrogen.

16. A process according to any of claims 12-15, wherein said process  
produces a compound of the formula I wherein  $R^1$  is 2-methoxy.

## INTERNATIONAL SEARCH REPORT

International Application No PCT/US 92/00113

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.C1.5 C 07 D 471/08 A 61 K 31/55 // (C 07 D 471/08 C 07 D 223:00 C 07 D 221:00 )		
II. FIELDS SEARCHED		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.C1.5	C 07 D	A 61 K
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
A	WO,A,9005729 (PFIZER) 31 May 1990, see claims 1-33 (cited in the application as PCT/US89/05338) -----	1, 4
<p><sup>6</sup> Special categories of cited documents :<sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
26-05-1992	30.06.92	
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer Nicole De Blie	

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V.  OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE<sup>1</sup>

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claim numbers 5, 7, 9, 11 because they relate to subject matter not required to be searched by this Authority, namely:

see rule 39.1(IV) PCT : Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2.  Claim numbers 12 because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out, specifically:

Claim 12 has been searched as if the final compounds were as described in claim 1.

3.  Claim numbers the second and third sentences of PCT Rule 6.4(a). because they are dependent claims and are not drafted in accordance with

VI.  OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING<sup>2</sup>

This International Searching Authority found multiple inventions in this International application as follows:

1.  As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application.
2.  As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims:
3.  No required additional search fees were timely paid by the applicant. Consequently, this International search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4.  As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- The additional search fees were accompanied by applicant's protest.
- No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO. US 9200113  
SA 56993**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on 22/06/92  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 9005729	31-05-90	WO-A- 9005525 CA-A- 2003441 EP-A- 0409931	31-05-90 23-05-90 30-01-91